Stock Fundamentals

Company Information

Company Name
argenx NV ADR
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US04016X1019
CIK: 0001697862
CUSIP: 04016X101
Currency: USD
Full Time Employees: 1,863
Phone: 31 10 703 8441
Fiscal Year End: December
IPO Date: May 18, 2017
Description:

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Address:

Laarderhoogtweg 25, Amsterdam, Netherlands, 1101 EB

Directors & Officers

Name Title Year Born
Mr. Timothy Van Hauwermeiren EMBA, M.Sc. Co-Founder & Non-Independent Non-Executive Chairman of the Board 1972
Ms. Karen Massey CEO & Executive Director 1979
Mr. Karl Gubitz Chief Financial Officer 1970
Dr. Peter Ulrichts Chief Scientific Officer 1980
Ms. Malini Moorthy General Counsel & Corporate Secretary 1970
Mr. Arjen Lemmen M.Sc. Vice President of Corporate Development & Strategy 1985
Ms. Andria Wilk Global Head of Quality 1974
Dr. Luc Truyen Chief Medical Officer 1965
Prof. Hans de Haard Ir, Ph.D. Co-Founder & Member of Board Advisors 1960
Mr. Filip Borgions Chief Technology Innovation Officer NA

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
FMR Inc 4.99M Mar 31, 2026 8.03% $0.19 -10.75%
T. Rowe Price Associates, Inc. 3.37M Mar 31, 2026 5.43% $0.28 0.38%
HHG PLC 2.54M Mar 31, 2026 4.09% $0.88 3.40%
Capital World Investors 2.26M Mar 31, 2026 3.63% $0.22 17.74%
Artisan Partners Limited Partnership 1.47M Mar 31, 2026 2.36% $1.72 -16.45%
Wellington Management Company LLP 1.02M Mar 31, 2026 1.64% $0.14 50.38%
venBio Select Advisor LLC 1.00M Mar 31, 2026 1.61% $7.18 1.01%
BlackRock Inc 808.34K Mar 31, 2026 1.30% $0.01 9.89%
RTW INVESTMENTS, LLC 709.45K Mar 31, 2026 1.14% $5.16 5.34%
Amvescap Plc. 594.70K Mar 31, 2026 0.96% $0.07 42.82%
Morgan Stanley - Brokerage Accounts 560.71K Mar 31, 2026 0.90% $0.02 8.07%
AllianceBernstein L.P. 422.30K Mar 31, 2026 0.68% $0.12 1.96%
Bank of America Corp 400.12K Mar 31, 2026 0.64% $0.02 -0.16%
Sands Capital Management, LLC 340.29K Mar 31, 2026 0.55% $0.98 -4.65%
Bellevue Group AG 313.00K Mar 31, 2026 0.50% $5.44 -32.23%
SEI Investments Co 286.97K Mar 31, 2026 0.46% $0.19 -13.17%
William Blair Investment Management, LLC 266.07K Mar 31, 2026 0.43% $0.64 18.96%
CI Private Wealth LLC 248.72K Dec 31, 2025 0.40% $0.00 12,550.92%
Jennison Associates LLC 237.47K Mar 31, 2026 0.38% $0.12 3.35%
Franklin Resources Inc 233.49K Mar 31, 2026 0.38% $0.04 -1.77%

Shares Statistics

Shares Outstanding: 62.19M
Shares Float: 1.55B
% Insiders: 0.30%
% Institutions: 4,763.60%
Short % Float: 2.33%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 American Funds EUPAC A 1.10M 1.76% ▲ 1.04% Mar 31, 2026
2 Capital Group EUPAC Composite 1.10M 1.76% ▲ 1.04% Mar 31, 2026
3 Fidelity Growth Compy Commingled Pl S 817.02K 1.31% ▲ 0.07% Apr 30, 2026
4 American Funds New Economy A 713.69K 1.15% ▲ 65.33% Mar 31, 2026
5 Capital Group New Economy Comp 713.69K 1.15% ▲ 65.33% Mar 31, 2026
6 Fidelity Growth Company Fund 609.07K 0.98% ▲ 0.00% Apr 30, 2026
7 Janus Concentrated Growth CF 537.87K 0.86% ▲ 0.00% Mar 31, 2026
8 Janus Henderson Forty S 537.87K 0.86% ▲ 0.00% Mar 31, 2026
9 Fidelity OTC 480.13K 0.77% ▼ 0.97% Apr 30, 2026
10 iShares Biotechnology ETF 337.91K 0.54% ▲ 1.46% May 29, 2026

Valuation Metrics

Enterprise Value: $49.70B
Trailing P/E: 38.92
Forward P/E: 33.56

Financial Highlights

Market Cap: $54.85B
EBITDA: $1.32B
P/E Ratio: $38.92
PEG Ratio: $1.49
Book Value: $4.73
Earnings/Share: $22.55
Profit Margin: 31.40%
Operating Margin: 30.01%
ROA (TTM): 8.86%
ROE (TTM): 20.15%
Revenue (TTM): $4.74B
Revenue/Share (TTM): $3.08
Earnings Growth (YOY): 114.00%
Revenue Growth (YOY): 62.60%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 5.23x 0.00x 0.16x 258.36x 0.01x
2024-12-31 7.29x 0.00x 0.11x -9.76x 0.06x
2023-12-31 9.75x 0.00x 0.10x -470.19x -0.02x
2022-12-31 9.18x 0.00x 0.10x -328.47x -0.01x
2021-12-31 8.44x 0.00x 0.11x -318.20x -0.01x
2020-12-31 6.26x 0.00x 0.27x -1,183.22x -0.01x
2019-12-31 8.58x 0.00x 0.27x -1,430.88x -0.01x
2018-12-31 14.29x 0.00x 0.07x -2.67x 0.00x
2017-12-31 14.96x 0.00x 0.07x -4.87x 0.00x
2016-12-31 3.15x 0.00x 0.40x N/A 0.00x
2015-12-31 5.12x 0.00x 0.19x N/A 0.00x
2014-12-31 5.60x 0.00x 0.14x -3,581.14x 0.00x
2013-12-31 7.38x 0.00x 0.13x -1,594.60x 0.00x
2012-12-31 3.58x 0.10x 0.27x -5,025.71x -0.13x
2011-12-31 7.81x 0.06x 0.13x -3,640.43x -0.40x
2010-12-31 5.86x 0.00x 0.17x N/A N/A

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ARGX.US!